Product Name: Balixafortide
CAS No: 1051366-32-5
Purity: 95%
Molar Mass: 1864.14
Chemical Formula: C84H118N24O21S2
Synonyms: POL6326
Storage: Store at -20℃
Sequence: Cyclo(ACSA-{D-Pro}-{Dab}-RYCYQK-{D-Pro}-PYH)
Target: CXCR4
Application: Balixafortide (CAS: 1051366-32-5) is a synthetic peptide-based antagonist of the CXCR4 receptor, a chemokine receptor involved in cell migration, homing, and survival. CXCR4 is overexpressed in various cancers, including breast cancer, prostate cancer, and certain hematological malignancies, where it plays a role in tumor progression, metastasis, and treatment resistance. Balixafortide functions by competitively binding to CXCR4, thereby blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as stromal cell-derived factor 1, SDF-1). This blockade disrupts signaling pathways critical for tumor cell migration, invasion, and survival in the tumor microenvironment. In pharmaceutical chemistry, balixafortide’s targeted antagonism of CXCR4 represents a promising approach to cancer therapy, offering a specific and effective means of inhibiting tumor progression and metastasis. Clinical trials are underway to evaluate its safety, efficacy, and therapeutic potential in different cancer types, with the goal of providing new treatment options for patients with advanced or metastatic disease.
